Regulatory Clearances of IND Applications for CR-001 & CR-003 for the Treatment of Solid Tumors Announced
“With regulatory clearances for CR-001 and CR-003, we are excited to begin 2026 with strong momentum as we work to deliver next generation therapies for people living with cancer,” said Ellie Im, M.D., chief medical officer of Crescent. “We are on track to have four clinical trials initiate across our portfolio in 2026, starting with the ASCEND trial of CR-001 planned for this quarter. Based on its intentional design replicating a clinically validated approach and robust preclinical profile demonstrating cooperative pharmacology and anti-tumor activity, we believe CR-001 has the potential to be a best-in-class therapy and immuno-oncology backbone.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data